#Randomization

Noah Haber

NoahHaber

Folks: There are serious statistical, design, language, and ethics concerns with that vitamin-D RCT.AT BEST, it's completely meaningless due to negligent statistical treatment and design, but there's more "questions"Help u

(((Jonathan Robinson)))

jon_m_rob

After thinking on it over the weekend, I have a couple of thoughts about this panel (both a bit negative + a tad contrarian it seems, though maybe just among

Francisco Marty, MD

FranciscoMarty_

Time to share some thoughts and questions following the .@medrxivpreprint first release of results from the #SolidarityTrial that compared local standard care to #remdesivir, #HydroxyChloroquine #lopinavir_ritonavir and #interferon for trea

F. Perry Wilson, MD MSCE

fperrywilson

This is a HUGE problem and not just because it is annoying, it will 100% exacerbate health disparities. (Thread)https://twitter.com/polly/status/1348464494108954626 My group is running a small (n=200) trial to see if

Carl T. Bergstrom

CT_Bergstrom

Last week, a press released provided initial and promising results from a large scale trial of the corticosteroid dexamethasone in hospitalized COVID patients. Today the authors released a full report:

Karl Pfleger

KarlPfleger

1/9 Big recent updates to #VitaminD #COVID19 evidence & thus now also to my review http://agingbiotech.info/vitamindcovid19 : 3 highly cited preprints are out but even better studies replace them, including finally

Francisco Marty, MD

FranciscoMarty_

With the .@NIAIDNews #ACCT1 trial final report published on 05 Nov 2020 and the .@WHO's #SolidarityTrial Preliminary report published on 02 December 2020, thought it would be good to take

Adrianna McIntyre

onceuponA

Good morning, I think we haven't talked enough yet about that new paper on cost-sharing for drugs in Medicare: https://tradeoffs.org/2021/02/19/the-deadly-costs-of-charging-patients-more-for-prescriptions/The findings are staggering, an

Rob Donoghue

rdonoghue

Ok, gonna talk about a thing I've seen kicking about. It's a disagreement, not a criticism, so I'm not tagging the inspiration, just because I think the sentiment was good,

Vinay Prasad MD MPH

VPrasadMDMPH

As someone who wrote a book on this topicEnding Medical Reversal (2015) w @adamcifu This article hurtsUnless you have a parachute-- and lets be clear-none of these drugs are parachutes--

Tim Hopper

tdhopper

Finished porting 30 repos to python 3 AMA Most changes are easy to fix automatically.Print statementsRelative to absolute imports Filter/map/dict.items/apply/range Standard library reorganization Exception catching syntax A few things were

Eric Meyerowitz, MD

EricMeyerowitz

1/ Thoughts on the exciting world of tocilizumab for treatment of COVID-19.RECOVERY tocilizumab preprint posted earlier today is another landmark paper and an enormous contribution to our expanding COVID-19 treatment

Gordon Shotwell 🇨🇦

gshotwell

I've been pretty bothered by the vitriol with which this paper is being received, and wanted to make a couple of points about how I read evidence like this:https://twitter.com/fperrywilson/status/1360944814271979523

LINK.eth ⬡

ray_v101

1/ #Chainlink is extending its reach is in the blockchain gaming industry, in which the project's price feeds and randomization tech are starting to gain traction and show their potential.

Stock-umm

steak_umm

friendly reminder in times of uncertainty and misinformation: anecdotes are not data. (good) data is carefully measured and collected information based on a range of subject-dependent factors, including, but not

Houston Institute

houstoninst

LONG THREAD: With today's announcement of substantial investment in data-driven pretrial criminal legal system reform, we are long-overdue for a broad conversation on addressing community needs, the role of philanthropy,

By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.